Skip to main content

Table 2 SCr levels in the LTE and Phase 3 studies: stabilization of SCr levels in the LTE studies

From: Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials

SCr increase at EoT in Phase 3 (%) Mean (%) increase from baseline at EoT in index study, mg/dl Mean (%) increase from baseline at last observed visit in LTE, mg/dl
≤10% (n = 909) 0.00 (0.3) 0.05 (7.5)
>10 to <33% (n = 653) 0.13 (18.6) 0.13 (18.5)
≥33 to ≤50% (n = 82) 0.25 (38.2) 0.24 (36.5)
>50% (n = 7) 0.32 (56.0) 0.26 (44.9)
  1. EoT, end of treatment; LTE, long-term extension; SCr, serum creatinine.